z-logo
Premium
The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer
Author(s) -
Weinberg Lori E.,
Rodriguez Gustavo,
Hurteau Jean A.
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21482
Subject(s) - medicine , ovarian cancer , chemotherapy , cytoreductive surgery , epithelial ovarian cancer , oncology , cancer
Abstract The current management of advanced ovarian cancer consists of aggressive primary cytoreductive surgery (PCS) followed by combination platinum based chemotherapy. Recent studies have suggested that platinum‐based chemotherapy may be of benefit in patients with advanced ovarian cancer prior to cytoreductive surgery (neoadjuvant chemotherapy, NACT). The concept of NACT has not been completely validated in the treatment of ovarian cancer. This review will discuss the role of NACT in patients with advanced epithelial ovarian cancer. J. Surg. Oncol. 2010; 101:334–343. © 2010 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here